Pharmacokinetics of the M1-agonist talsaclidine in mouse, rat, rabbit and monkey, and extrapolation to man

Xenobiotica

Volumn 30, Issue 8, 2000, Pages 797-814

  Leusch, A ^a   Troger, W ^a   Greischel, A ^a   Roth, W ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MUSCARINIC M1 RECEPTOR AGONIST; TALSACLIDINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG PROTEIN BINDING; MONKEY; MOUSE; NONHUMAN; RABBIT; RAT;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 0033865352     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250050119853     Document Type: Article

References (28)

1. Phase I clinical trials with WAL 2014, a new muscarinic agonist for the treatment of Alzheimer's disease
2. Discriminative stimulus properties of the muscarinic receptor agonists Lu 26-046 and O-Me-THPO in rats: Evidence for involvement of different muscarinic receptor subtypes
3. Donepezil use in Alzheimer disease
4. Design of [R-(Z)]-(+)-alpha-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitrile (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere
5. Xanomeline compared with other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects
6. Correlation of plasma clearance of 54 extensively metabolized drugs between humans and rats: Mean allometric coefficient of 0.66
7. Tacrine in Alzheimer's disease
8. Physiological parameters in laboratory animals and humans
9. Effects of the M1 agonist xanomeline on processing of human beta-amyloid precursor protein (FAD, Swedish mutant) transfected into Chinese hamster ovary-m1 cells
10. WAL 2014 FU (talsaclidine): A preferentially neuron activating muscarinic agonist for the treatment of Alzheimer's disease
11. WAL 2014 - A muscarinic agonist with preferential neuron-stimulating properties
12. Invited Review: Cholinesterase inhibitors for Alzheimer's disease therapy: From tacrine to future applications
13. Gender differences in pharmacokinetics
14. Non-compartmental analyses: Methods
15. Muscarinic receptor subtypes
16. Interspecies scaling and comparison in drug development and toxicokinetics
17. The cognitive psychopharmacology of Alzheimer's disease: Focus on cholinergic systems
18. Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics
19. Sex-dependent pharmacokinetics of indinavir: In vivo and in vitro evidence
20. Autoradiographic analyses of agonist binding to muscarinic receptor subtypes
21. Link between drug absorption and permeability measurements in CaCo-2 cells
22. Metabolism and excretion of a novel antianxiety drug candidate, CP-93,393, in Long-Evans rats
23. Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study
24. Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies
25. A bridging study of LU 25-109 in patients with probable Alzheimer's disease
26. Sex differences in excretion of zenarestat in rat
27. Specificity of transporters for organic anions and organic cations in the kidney